论文部分内容阅读
英《医学新闻周刊》第13卷第18期(1981年)报道:早已知道钙离子透过心脏和血管系统兴奋的细胞膜的活动是保持心肌收缩力和血管张力的基本要求。但是,只是在最近10年内才研制成能够拮抗这些钙离子流的药物,因而大大改变心血管的功能。最近在伦敦皇家医师学院由联合王国拜耳公司召开的一次座谈会上,集中提出这些钙拮抗剂对心血管疾病的广泛用途。钙拮抗剂是一组有多种化学成分的化合物,具有抑制钙向内移动透过心肌及血管平滑肌细胞膜的作用。这些化合物中有些具有一种特别重要的特性是它
British Medical News Weekly Volume 13, No. 18 (1981) reported: It has long been known that calcium ions through the heart and vascular system excited cell membrane activity is to maintain myocardial contractility and vascular tension of the basic requirements. However, drugs developed to antagonize these calcium currents have only been developed in the last 10 years, thereby dramatically modifying cardiovascular function. At a recent Symposium held by the Royal College of Physicians in London, Bayer, UK, the use of these calcium antagonists for a wide range of cardiovascular diseases was focused. Calcium antagonists are compounds that have a variety of chemical constituents that inhibit the inward movement of calcium through the myocardium and vascular smooth muscle cell membranes. Some of these compounds have a particularly important trait of it